Hepatic Amyloidosis – A Clinicoradiological Dido

Archana A Randale¹, Sanjay N Parate², Saroj A Meshram¹, Shilpa P Tathe¹, Milind A Bhatkule¹

ABSTRACT
Amyloidosis is a wide spectrum of disease characterized by extracellular deposition of misfolded protein that aggregates to form insoluble fibrils. These fibrils have common morphological, structural, and staining properties but differ in protein composition.[1] The worldwide estimated incidence of amyloidosis is 5–9 cases per million patients per year.[2] Practically no organ/tissues are spared from infiltration by amyloid fibrils. However, clinically dominant hepatic amyloidosis presenting as diffusely infiltrative disease in the form of massive hepatomegaly with preserved hepatic function is unusual.[3,4]

Here, we report a case of hepatic amyloidosis with preserved liver function test despite having massive hepatomegaly.

Introduction
Amyloidosis is a wide spectrum of disease characterized by extracellular deposition of misfolded protein that aggregates to form insoluble fibrils. These fibrils have common morphological, structural, and staining properties but differ in protein composition.[1] The worldwide estimated incidence of amyloidosis is 5–9 cases per million patients per year.[2] Practically no organ/tissues are spared from infiltration by amyloid fibrils. However, clinically dominant hepatic amyloidosis presenting as diffusely infiltrative disease in the form of massive hepatomegaly with preserved hepatic function is unusual.[3,4]

Blood investigation was done showed normal levels of liver enzymes (alanine aminotransferase – 31 U/L, aspartate aminotransferase – 46 U/L, alkaline phosphatase–70 U/L, and bilirubin 1.2 mg/dl) and kidney function test (blood urea nitrogen – 32 mg/dl and serum creatinine – 0.8 mg/dl). Hemogram revealed normocytic normochromic anemia with total white blood cells and platelet count within normal limits. Erythrocyte sedimentation rate was 20 mm of Hg. Triple H markers (HIV, HBsAg, and HCV) were negative.

With this clinical history and baseline investigations, the patient was subjected to computed tomography of abdomen which showed grossly enlarged liver with disproportionate enlargement of the left lobe of liver. Liver was measuring 21 cm craniocaudally. There was no evidence of any focal lesion in the liver [Figure 1]. Radiological diagnosis offered was diffusely infiltrative liver pathology. Upper gastrointestinal endoscopy was also done and did not show any significant pathology.

To overcome with this clinicoradiological camouflage, liver biopsy was done which showed deposition of amorphous acellular eosinophilic material between and around hepatocytes. Hepatocytes appeared compressed and atrophic at places [Figure 2]. With

Case Report
A 42-year-old female presented with history of dull aching, non-radiating pain in the right hypochondriac, and epigastric region with distension of abdomen for 2 months. Furthermore, she had history of loss of appetite and breathlessness for 1 month. There was no history of jaundice, itching, altered bowel habit, or altered sensorium. There was no history of major illness in the past. On examination, patient was conscious, oriented with vitals within normal limits. However, on per abdominal examination, liver was palpable 5 cm below the costal margin with smooth surface, rounded borders, and firm consistency.

Here, we report a case of hepatic amyloidosis with preserved liver function test despite having massive hepatomegaly.
high suspicion for amyloid deposits on hematoxylin and eosin stain, Congo red stain was advised which showed positive congophilia [Figure 3]. Further to know the type of amyloid, immunohistochemistry was done [Figure 4]. It showed apple-green birefringence under polarized microscope and strong positivity for serum amyloid associated (SAA) protein. Thus, confirming the diagnosis of hepatic amyloidosis (AA type). Serum electrophoresis was also done and did not reveal any M band.

Due to her complaint of breathlessness, two-dimensional (2D) echo was done which showed features of the nonobstructive type of hypertrophic cardiomyopathy suggestive of some infiltrative pathology.

Discussion
Amyloidosis is a wide spectrum of disease characterized by extracellular deposition of misfolded protein that aggregates to form insoluble fibrils. These fibrils have common morphological, structural, and staining properties but differ in protein composition. It is this protein deposited determines the type of amyloid.[1,5]

Two principle types of amyloidosis are:
1. Myeloma–associated light chain immunoglobulin (AL) type also called as primary amyloidosis.
2. AA protein is responsible for secondary or reactive amyloidosis. This type is associated with chronic infectious/inflammatory diseases such as tuberculosis (50%), bronchiectasis, chronic osteomyelitis, and autoimmune disorders such as rheumatoid arthritis (20–25%).[4-6]

Other rare types of amyloidosis include dialysis associated β₂ microglobulin-related amyloidosis and familial amyloidosis polyneuropathy.[1]

At present, the AA/AL ratio is 1:17–1:38. This may be due to increasing recognition of myeloma associated amyloidosis and advanced treatment modalities for infectious/inflammatory diseases.[7]

Systemic primary AL amyloidosis mainly involves tongue, heart, gut, muscle, nerve, and skin whereas secondary amyloidosis involves liver, spleen, kidney, and adrenal gland predominantly.[8] Hepatic involvement is more common with secondary AA amyloidosis and presents as diffuse infiltration.[9]

Hepatic amyloidosis starts with deposition of amyloid in the space of Disse first, progressively encroaching on to adjacent hepatic parenchyma.
and sinusoids. As the disease advances, deformity, pressure atrophy, and disappearance of hepatocytes can occur resulting in total replacement of large areas of liver parenchyma. With this massive infiltration liver gets a rubbery, elastic consistency resulting in what is called as “lardaceous liver” appearance on cut surface.\textsuperscript{[10]}

Clinically, these patients mostly have mild manifestations with preserved hepatic function despite severe liver encroachment.\textsuperscript{[11]} Radiological findings of hepatic amyloidosis can be non-specific in the form of diffusely infiltrative hepatic pathology.\textsuperscript{[12]}

![Figure 4: Result of immunohistochemistry and polarized microscopy](image)

In our case also, with these camouflaging clinicoradiological features, liver biopsy and thereby histopathological evaluation was done for confirmative diagnosis. The amyloid characteristically appears as acellular pale eosinophilic and amorphous material on routine hematoxylin and eosin stain. When stained with Congo red, it shows salmon red color on light microscopy and apple-green birefringence under polarized microscopy. Further typing of amyloid deposited can be done using ancillary histopathologic technique like immunohistochemical staining for monoclonal proteins such as kappa, lambda chains, and protein SAA.\textsuperscript{[13]} In our case, the mystery
behind the type of amyloid deposited was solved by immunohistochemistry.

Hepatic amyloid deposits in systemic AA amyloidosis are typically associated with significant amyloid deposition in other organs when present carries a poor prognosis. The other organ involvements can present as nephrotic syndrome, congestive cardiac failure, high bilirubin, and high platelet count which are some of the predictors of poor prognosis in these patients. Our patient also had the nonobstructive type of hypertrophic cardiomyopathy on 2D echo and succumbs to death within 6 months of the initial diagnosis of hepatic amyloidosis.

Conclusion
Hepatic amyloidosis can present as clinicoradiological dido and requires liver biopsy and ancillary histopathological techniques not only to attest the diagnosis but also for typing of amyloidosis. The presence of cardiac involvement is associated with poor outcomes in these patients.

References
1. Sonthalia N, Jain S, Pawar S, Zanwar V, Surude R, Rathi P. Primary hepatic amyloidosis: A case report and review of literature. World J Hepatol 2016;8:340-4.
2. Rastogi M, Bansal N, Aungshan M, Vij V. Hepatic amyloidosis-when looks are deceptive. J Cytol Histol 2018;9:520.
3. Lachmann HJ, Goodman HJ, Gilbertson JA, Hawkins PN. Natural history and outcome in systemic AA amyloidosis. N Engl J Med 2007;356:2361-71.
4. Buxbaum JN, Linke RP. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Canada: Elsevier Saunders; 2015. p. 256-62.
5. Nair AV, Yadav MK, Unni MN, Simi CM, Biju KA, Manoj KS, et al. Hepatic amyloidosis: Something that can camouflage and deceive our perception. Indian J Med Paediatr Oncol 2017;38:236-9.
6. Shin YM. Hepatic amyloidosis. Korean J Hepatol 2011;17:80-3.
7. Park MA, Mueller PS, Kyle RA, Larson DR, Plevak MF, Gertz MA. Primary (AL) hepatic amyloidosis: Clinical features and natural history in 98 patients. Medicine (Baltimore) 2003;82:291-8.
8. Pinney JH, Smith CJ, Taube JB. Systemic amyloidosis in England: An epidemiological study. Br J Haematol 2013;161:525-32.
9. Gullu BE, Hatem I, Ozbay G, Tuzener N, Sonsuz A. A rare case of primary systemic amyloidosis presenting with hepatic failure. Turk J Gastroenterol 2011;22:113-4.
10. Monzawa S, Tsukamoto T, Onato K, Hosoda K, Araki T, Sugimura K. A case with primary amyloidosis of the liver and spleen: Radiologic findings. Eur J Radiol 2002;41:237-41.
11. Kim SH, Han JK, Lee KH, Won HJ, Kim KW, Kim JS, et al. Abdominal amyloidosis: Spectrum of radiological finding. Clin Radiol 2003;58:610-20.
12. Mainenti PP, Agostino L, Soschia E, Romano M, Salvatore M. Hepatic and splenic amyloidosis: Dual phase spiral CT findings. Abdom Imaging 2003;28:688-90.
13. Ibrahim A, Fayaz AH, Khaled OA, Adel G. Fatal subacute hepatic failure in a patient with AA-type amyloidosis: Case report. Patholog Res Int 2010;2010:648089.
14. Lovat LB, Persey MR, Madhoo S, Pepys MB, Hawkins PN. The liver in systemic amyloidosis: Insights from serum amyloid P component scintigraphy in 484 patients. Gut 1998;42:727-34.
15. Gertz MA, Kyle RA. Hepatic amyloidosis (Primary [AL], immunoglobulin light chain): The natural history in 80 patients. Am J Med 1988;85:73-80.

Financial Support: None; Conflicts of Interest: None

How to cite this article: Randale AA, Parate SN, Meshram SA, Tathe SP, Bhatkule MA. Hepatic Amyloidosis – A Clinicoradiological Dido. J Med Sci Health 2019;5(3):44-47.

Date of submission: 06-10-2019
Date of review: 25-10-2019
Date of acceptance: 01-12-2019
Date of publication: 10-02-2020